XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Fair value of financial instruments and marketable securities - (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis

March 31, 2021

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

642,077

$

$

642,077

$

Marketable securities - equity investments

$

199,697

$

199,697

$

$

ClearPoint Equity Investments

$

27,367

$

27,367

$

$

ClearPoint convertible debt security

$

37,109

$

$

37,109

$

Contingent consideration payable- development and regulatory milestones

$

139,300

$

$

$

139,300

Contingent consideration payable- net sales milestones and royalties

$

101,200

$

$

$

101,200

December 31, 2020

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

894,838

$

$

894,838

$

ClearPoint Equity Investments

$

20,503

$

20,503

$

$

ClearPoint convertible debt security

$

29,252

$

$

29,252

$

Contingent consideration payable- development and regulatory milestones

$

139,200

$

$

$

139,200

Contingent consideration payable- net sales milestones and royalties

$

101,200

$

$

$

101,200

Summary of marketable securities accounted for as available-for-sale debt securities

March 31, 2021

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

252,778

$

25

$

(1)

$

252,802

Corporate debt securities

 

330,781

 

591

 

(139)

 

331,233

Asset-backed securities

 

19,216

 

104

 

 

19,320

Government obligations

38,696

30

 

(4)

38,722

Total

$

641,471

$

750

$

(144)

$

642,077

December 31, 2020

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

276,855

$

19

$

(37)

$

276,837

Corporate debt securities

 

474,030

 

1,658

 

(29)

 

475,659

Asset-backed securities

 

28,681

 

210

 

(3)

 

28,888

Government obligations

113,372

88

(6)

113,454

Total

$

892,938

$

1,975

$

(75)

$

894,838

Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position

March 31, 2021

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than 12 months

Total

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

Commercial paper

$

(1)

69,096

(1)

69,096

Corporate debt securities

(139)

177,817

(139)

177,817

Asset-backed securities

 

 

 

 

 

 

Government obligations

(4)

19,137

(4)

19,137

Total

$

(144)

$

266,050

$

$

$

(144)

$

266,050

December 31, 2020

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than 12 months

Total

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

Commercial paper

$

(37)

129,630

(37)

129,630

Corporate debt securities

(29)

102,426

(29)

102,426

Asset-backed securities

 

(3)

 

1,830

 

 

 

(3)

 

1,830

Government obligations

(6)

27,084

(6)

27,084

Total

$

(75)

$

260,970

$

$

$

(75)

$

260,970

Schedule of marketable securities on the balance sheet

March 31, 2021

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

252,802

$

Corporate debt securities

 

164,640

 

166,593

Asset-backed securities

 

5,321

 

13,999

Government obligations

28,160

10,562

Total

$

450,923

$

191,154

December 31, 2020

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

276,837

$

Corporate debt securities

 

240,139

 

235,520

Asset-backed securities

 

6,363

 

22,525

Government obligations

65,524

47,930

Total

$

588,863

$

305,975

Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2020

$

139,200

$

101,200

Additions

 

 

Change in fair value

 

100

 

Payments

Ending balance as of March 31, 2021

$

139,300

$

101,200

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

    

milestones

    

Beginning balance as of December 31, 2019

$

290,500

$

65,800

Additions

 

 

Change in fair value

 

(16,600)

 

17,500

Payments

Ending balance as of March 31, 2020

$

273,900

$

83,300

Fair Value Measurement Inputs and Valuation Techniques

March 31, 2021

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$139,300

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $381 million
25% - 94%
1.5% - 4.9%
2021 - 2028

Contingent considerable payable- net sales
milestones and royalties

$101,200

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 94%
2% - 6%
12.5%
2022 - 2040

December 31, 2020

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$139,200

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $381 million
25% - 94%
2.2% - 4.5%
2021 - 2028

Contingent considerable payable- net sales
milestones and royalties

$101,200

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 94%
2% - 6%
11.5%
2022 - 2040